{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:33:29Z","timestamp":1707525209218},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,19]]},"DOI":"10.7759\/cureus.42118","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T12:54:56Z","timestamp":1689771296000},"source":"Crossref","is-referenced-by-count":0,"title":["Anti-Ro52\/Anti-nuclear Matrix Protein 2 Positive Clinically Amyopathic Dermatomyositis Presented Only With Interstitial Lung Disease"],"prefix":"10.7759","author":[{"given":"Stratos","family":"Skrimizeas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilias E","family":"Dimeas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Dimeas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Argyrios","family":"Tzouvelekis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Daniil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.00002015","article-title":"Idiopathic inflammatory myopathies and the lung","volume":"24","author":"Lega JC","year":"2015","unstructured":"Lega JC, Reynaud Q, Belot A, Fabien N, Durieu I, Cottin V. Idiopathic inflammatory myopathies and the lung. Eur Respir Rev. 2015, 24:216-38. 10.1183\/16000617.00002015","journal-title":"Eur Respir Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2019.100013","article-title":"Frequencies and clinical associations of myositis-related antibodies in the Netherlands: a one-year survey of all Dutch patients","volume":"2","author":"Platteel AC","year":"2019","unstructured":"Platteel AC, Wevers BA, Lim J, et al.. Frequencies and clinical associations of myositis-related antibodies in the Netherlands: a one-year survey of all Dutch patients. J Transl Autoimmun. 2019, 2:100013. 10.1016\/j.jtauto.2019.100013","journal-title":"J Transl Autoimmun"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1096203","article-title":"Clinical features and outcomes of patients with myositis associated-interstitial lung disease","volume":"9","author":"Karampitsakos T","year":"2022","unstructured":"Karampitsakos T, Tzilas V, Papaioannou O, et al.. Clinical features and outcomes of patients with myositis associated-interstitial lung disease. Front Med (Lausanne). 2022, 9:1096203. 10.3389\/fmed.2022.1096203","journal-title":"Front Med (Lausanne)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.211234","article-title":"Clinical heterogeneity of patients with antinuclear matrix protein 2 antibody-positive myositis: a retrospective cohort study in China","volume":"49","author":"Li S","year":"2022","unstructured":"Li S, Sun C, Zhang L, et al.. Clinical heterogeneity of patients with antinuclear matrix protein 2 antibody-positive myositis: a retrospective cohort study in China. J Rheumatol. 2022, 49:922-8. 10.3899\/jrheum.211234","journal-title":"J Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.103013","article-title":"An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management","volume":"21","author":"Decker P","year":"2022","unstructured":"Decker P, Moulinet T, Pontille F, Cravat M, De Carvalho Bittencourt M, Jaussaud R. An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management. Autoimmun Rev. 2022, 21:103013. 10.1016\/j.autrev.2021.103013","journal-title":"Autoimmun Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2023.02.009","article-title":"Antisynthetase syndrome with predominant lung involvement. An easy to miss diagnosis","volume":"29","author":"Tzilas V","year":"2023","unstructured":"Tzilas V, Ryu JH, Sfikakis PP, Tzouvelekis A, Bouros D. Antisynthetase syndrome with predominant lung involvement. An easy to miss diagnosis. Pulmonology. 2023, 29:271-2. 10.1016\/j.pulmoe.2023.02.009","journal-title":"Pulmonology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-022-05176-3","article-title":"New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review","volume":"42","author":"Holzer MT","year":"2022","unstructured":"Holzer MT, Krusche M, Ruffer N, Haberstock H, Stephan M, Huber TB, K\u00f6tter I. New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review. Rheumatol Int. 2022, 42:2267-76. 10.1007\/s00296-022-05176-3","journal-title":"Rheumatol Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab872","article-title":"Anti-NXP2 antibody-positive dermatomyositis developed after COVID-19 manifesting as type I interferonopathy","volume":"61","author":"Okada Y","year":"2022","unstructured":"Okada Y, Izumi R, Hosaka T, et al.. Anti-NXP2 antibody-positive dermatomyositis developed after COVID-19 manifesting as type I interferonopathy. Rheumatology (Oxford). 2022, 61:e90-2. 10.1093\/rheumatology\/keab872","journal-title":"Rheumatology (Oxford)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2022.03.023","article-title":"Cancer associated autoantibodies in idiopathic inflammatory myopathies: a retrospective cohort from a single center in China","volume":"160","author":"Zhao Y","year":"2023","unstructured":"Zhao Y, Su H, Yin X, et al.. Cancer associated autoantibodies in idiopathic inflammatory myopathies: a retrospective cohort from a single center in China. Med Clin (Barc). 2023, 160:10-6. 10.1016\/j.medcli.2022.03.023","journal-title":"Med Clin (Barc)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy","volume":"71","author":"Ichimura Y","year":"2012","unstructured":"Ichimura Y, Matsushita T, Hamaguchi Y, et al.. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012, 71:710-3. 10.1136\/annrheumdis-2011-200697","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/lqjx4h","article-title":"Interstitial lung disease in adult patients with anti-NXP2 antibody positivity: a multicentre 18-month follow-up study","volume":"41","author":"Yan T","year":"2023","unstructured":"Yan T, Du Y, Sun W, et al.. Interstitial lung disease in adult patients with anti-NXP2 antibody positivity: a multicentre 18-month follow-up study. Clin Exp Rheumatol. 2023, 41:247-53. 10.55563\/clinexprheumatol\/lqjx4h","journal-title":"Clin Exp Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2020.1767598","article-title":"Lung involvement associated with anti-NXP2 autoantibodies in inflammatory myopathies: a French monocenter series","volume":"14","author":"Bermudez J","year":"2020","unstructured":"Bermudez J, Heim X, Bertin D, Coulon B, Puech B, Bardin N, Reynaud-Gaubert M. Lung involvement associated with anti-NXP2 autoantibodies in inflammatory myopathies: a French monocenter series. Expert Rev Respir Med. 2020, 14:845-50. 10.1080\/17476348.2020.1767598","journal-title":"Expert Rev Respir Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.01.031","article-title":"Diagnosis and management of myositis-associated lung disease","volume":"163","author":"Hallowell RW","year":"2023","unstructured":"Hallowell RW, Danoff SK. Diagnosis and management of myositis-associated lung disease. Chest. 2023, 163:1476-91. 10.1016\/j.chest.2023.01.031","journal-title":"Chest"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/170359-anti-ro52anti-nuclear-matrix-protein-2-positive-clinically-amyopathic-dermatomyositis-presented-only-with-interstitial-lung-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:00:37Z","timestamp":1707508837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/170359-anti-ro52anti-nuclear-matrix-protein-2-positive-clinically-amyopathic-dermatomyositis-presented-only-with-interstitial-lung-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.42118","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,19]]}}}